Mikhail V. Nesterchuk

Mikhail V. Nesterchuk

Auto-generated profile, based on publicly available information

Mikhail V. Nesterchuk

GenTerra JSC

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2022 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
ASAnastasiia Yu. Sapach
Anastasiia Yu. Sapach
Olga SindeevaOlga Sindeeva
Olga Sindeeva
MNMikhail V. Nesterchuk
Mikhail V. Nesterchuk
ATAleksandra A Tsitrina
Aleksandra A Tsitrina
OMOksana Mayorova
Oksana Mayorova
Gleb SukhorukovGleb Sukhorukov
Gleb Sukhorukov

7 August 2026 in Burdenko's Journal of Neurosurgery
Verified
Journal Article
Closed access
GSG.S. Sergeev
G.S. Sergeev
MNM.V. Nesterchuk
M.V. Nesterchuk
VKVladimir Klimov
Vladimir Klimov
AGA.S. Gaytan
A.S. Gaytan
VKV.V. Kuftov
V.V. Kuftov
AKAlexey Krivoshapkin
Alexey Krivoshapkin
Background. Traditional histological classification of meningiomas has low prognostic accuracy and necessitates integration of molecular biomarkers. However, current data are fragmented and require rigorous synthesis. Objective. To develop a meta-analysis protocol for quantitative assessment of the influence of molecular profile of meningiomas on long-term outcomes (overall survival and recurrence-free period) after surgical or combined treatment. Material and methods. The article provides historical analysis of transformation of evidence-based medicine standards from narrative reviews to algorithmic guidelines (QUOROM, MOOSE, PRISMA). The choice of the PRISMA-P 2020 protocol and Cochrane methodology as the standard for this study is justified. Results. A meta-analysis design was developed to assess the impact of genetic profile (TERT, CDKN2A/B, NF2 status, DNA methylation) on the risk of recurrence. Inclusion criteria (PICOTS) cover all types of meningiomas. The protocol regulates searching strategy, independent screening (Rayyan) and risk of bias assessment using the QUIPS tool. Statistical synthesis of data is planned to identify the hierarchy of risk factors. Conclusion. Implementation of this protocol will ensure creation of a valid evidence base for stratification of risk of meningioma recurrence based on molecular genetic profile.

16 October 2026 in Burdenko's Journal of Neurosurgery
Verified
Journal Article
Closed access
GSG.S. Sergeev
G.S. Sergeev
MNM.V. Nesterchuk
M.V. Nesterchuk
VKVladimir Klimov
Vladimir Klimov
AGA.S. Gaytan
A.S. Gaytan
VKV.V. Kuftov
V.V. Kuftov
AKAlexey Krivoshapkin
Alexey Krivoshapkin
Background. Evolution of the WHO classification for meningiomas demonstrates a shift towards integrative approach, where molecular markers are essential for risk stratification. However, their prognostic significance depending on histological grade requires further clarification. Objective. To evaluate the impact of TERT promoter mutations and CDKN2A/B deletions on meningioma recurrence, stratified by tumor grade. Material and methods. A systematic review and meta-analysis (PRISMA-P) of 17 cohort studies (n=5867) was conducted. Random-effect models and network meta-analysis were employed to assess overall survival (OS) and progression-free survival (PFS). Results. The TERT mutation significantly worsens prognosis (OS HR=2.78; PFS HR=2.63), but the effect is context-dependent. In WHO Grade 1–2 tumors, it acts as a potent driver of aggression (HR~5.00, “initiation effect”), whereas in Grade 3 its contribution diminishes (HR~1.5) amidst general genomic instability. Homozygous deletion of CDKN2A/B is confirmed as a universal marker of early recurrence (HR=3.72) with up to 5-fold risk increment. Sensitivity analysis revealed that clonal mutations (detected by Sanger sequencing) hold greater prognostic value than subclonal ones (detected by NGS). Conclusion. TERT screening is essential for WHO Grade 1 and 2 meningiomas to identify occult aggression, while CDKN2A/B assessment is a priority for Grade 3 tumors.